Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies | Read More in our Press Releases

Our vision

Expanding the life-changing benefits of cell therapies.

Our science

Transforming cell therapy, one cell at a time.

Our pipeline

Working to deliver better outcomes through our clinical programs.

At Orca Bio, we believe all patients deserve a chance at a cure

We don’t settle, and we believe patients shouldn’t have to

If you are interested in joining our team, learn about our collaborative culture and patient-driven mission.

Stay up to date with our developments—review our press releases in the newsroom.

Now Approved in the U.S.

To learn more:

View Our Press Release